Mar 28, 2022 / 03:30PM GMT
Paul Matteis - Stifel Financial Corp. - Analyst
Great. Thank you very much, everybody. It's my pleasure to be hosting a panel here with the Alector executive team. We will have a lot of different things to talk about.
Paul Matteis - Stifel Financial Corp. - Analyst
But maybe to start, I can kick it over to Arnon to give an update and overview of the key mid- to late-stage Alector programs. How does that sound?
Arnon Rosenthal - Alector, Inc. - Co-Founder, CEO, & Director
Sounds great. Thank you for the invite, Paul.
So as you know, Alector mission is to recruit the brain immune system to counteract multiple disease pathologies in neurodegeneration. And with this approach, we now have multiple clinical programs. Our most advanced program is 001. It's a progranulin-elevating drug, and it is now in a registrational Phase 3 in frontotemporal dementia patients with progranulin mutations. In addition, the same drug is in open-label Phase 2 in progranulin mutation carriers with FTD and C9orf mutation carries
Alector Inc at Stifel CNS Days (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers